Skip to main content Skip to search Skip to main navigation

CHMP: Extended Deadline for Nitrosamine Step 3 Revision and Q&A update

The Committee for Medicinal Products for Human Use (CHMP) and the CMDh (Coordination Group on Mutual Recognition Procedures and Decentralised Procedures) of the EMA extended the deadline for submission of variation applications under Step 3: "Variation of marketing authorisation for chemical medicinal products" from 26 September 2022 to 1 October 2023.

The extension is to allow companies to carry out a thorough investigation and identify any necessary risk mitigation measures, in particular regarding nitrosamines that may result from active substances. This extension does not affect the deadline for the completion of the level 2 confirmatory tests for chemical medicinal products. This will continue to end on 26 September 2022, by which time marketing authorisation holders should submit the full results of stage 2.

Certificates of Suitability
A similar approach is taken for Certificates of Suitability (CEP) and therefore the previously announced deadline (notice to all CEP holders for synthetic active substances regarding the presence of nitrosamines) for the submission of all necessary revisions under Step 3 is thus extended to 1 October 2023. Nevertheless, CEP holders are invited to submit their amendments as soon as the investigations are completed and thus before the deadline mentioned above.


Q&A document on nitrosamine impurities
The changes are also reflected in the accompanying Q&A document. Question 3 on the “call for review” has been updated accordingly:

  • For product containing chemically synthesised APIs, confirmatory testing activities at Step 2 are expected to be finalized at the latest by 26th September 2022.
  • The deadline for the submission of any changes required to Marketing Authorisations is by 1 October 2023.
  • For product containing biological APIs, confirmatory testing activities at Step 2 and submission of any changes required to Marketing Authorisations are expected to be finalized at the latest by 1 July 2023.

Source:

EMA: Q&A on nitrosamine impurities in human medicinal products
EMA: Nitrosamine impurities website

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next